Holen Sie sich die Stockscreener-App
89.79
0.04%
-0.04
Handel nachbörslich:
89.79
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$89.83
Offen:
$89.89
24-Stunden-Volumen:
2.82M
Relative Volume:
0.60
Marktkapitalisierung:
$51.75B
Einnahmen:
$6.30B
Nettoeinkommen (Verlust:
$1.07B
KGV:
48.78
EPS:
1.8406
Netto-Cashflow:
$1.09B
1W Leistung:
-1.98%
1M Leistung:
+6.20%
6M Leistung:
+12.55%
1J Leistung:
+10.63%
1-Tages-Spanne:
$88.79
$90.37
1-Wochen-Bereich:
$88.79
$93.25
52-Wochen-Spanne:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
89.79 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
116.64 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
329.45 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
93.35 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
50.37 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
40,124 Shares in Edwards Lifesciences Corporation $EW Acquired by Wealthfront Advisers LLC - MarketBeat
Tocqueville Asset Management L.P. Makes New $5.37 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Fairtree Asset Management Pty Ltd Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Bank of New York Mellon Corp Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event? - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences stock holds gains as Q2 growth supports 2026 outlook - Ad-hoc-news.de
Should You Hold Edwards Lifesciences Stock in Your Portfolio? - Yahoo Finance
Global Cardiovascular Devices Market to Reach $101.6 Billion by 2030, Says BCC Research Analyst - GlobeNewswire
524,490 Shares in Edwards Lifesciences Corporation $EW Acquired by Danske Bank A S - MarketBeat
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years - Benzinga
Aristotle Capital Management, LLC's Edwards Lifesciences Corp(EW) Holding History - GuruFocus
Mitsubishi UFJ Asset Management Co. Ltd. Takes $126.12 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care - Yahoo Finance
BlackRock Inc. Acquires New Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock holds steady as analysts see upside - AD HOC NEWS
OneDigital Investment Advisors LLC Takes $1.27 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Deutsche Bank AG Invests $516.55 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Oppenheimer Asset Management Inc. Purchases Shares of 22,090 Edwards Lifesciences Corporation $EW - MarketBeat
AMG National Trust Bank Invests $6.83 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Maridea Wealth Management LLC Purchases New Position in Edwards Lifesciences Corporation $EW - MarketBeat
Bank Hapoalim BM Makes New $1.78 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Empowered Funds LLC Boosts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
ABN AMRO Bank N.V. Makes New $83.57 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Everett Harris & Co. CA Acquires Shares of 80,341 Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
EW|Edwards Lifesciences Corp|Price:90.865|Chg%:-0.735 - TradingKey
$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today - Benzinga
Seascape Capital Management's Edwards Lifesciences Corp(EW) Holding History - GuruFocus
Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock? - Barchart.com
Edwards Lifesciences CVP sells $56,966 in company stock By Investing.com - Investing.com Nigeria
Edwards Lifesciences CVP sells $56,966 in company stock - Investing.com
Edwards Lifesciences (EW) Insider Daniel Lippis Sells 619 Shares - GuruFocus
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences (EW) insider files Form 144 for cashless option exercise - Stock Titan
Handelsbanken Fonder AB Has $139.42 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
29,000 Shares in Edwards Lifesciences Corporation $EW Bought by Renaissance Technologies LLC - marketbeat.com
Edwards Lifesciences Corporation $EW is Seilern Investment Management Ltd's 4th Largest Position - MarketBeat
Orser Capital Management LLC Invests $2.32 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Assenagon Asset Management S.A. Acquires 547,212 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Fund Update: 525,889 EDWARDS LIFESCIENCES (EW) shares added to ABN AMRO Bank N.V. portfolio - Quiver Quantitative
Segall Bryant & Hamill LLC Acquires New Stake in Edwards Lifesciences Corporation $EW - MarketBeat
EW CLASS ACTION FINAL DEADLINE: Edwards Lifesciences Investors are Notified that Today is the Final Deadline in Securities Fraud Class Action and are Urged to Contact BFA Law - TMX Newsfile
Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match - Yahoo Finance
Is It Too Late to Buy Edwards Lifesciences Corp (EW) After 3.2% Rally? GF Value Says Undervalued - GuruFocus
Bank of America Corp DE Acquires 2,212,208 Shares of Edwards Lifesciences Corporation $EW - marketbeat.com
Groupama Asset Managment Purchases New Position in Edwards Lifesciences Corporation $EW - marketbeat.com
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.35%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):